Navigation Links
Standard Heart Drugs Won't Ease Pulmonary Hypertension

WEDNESDAY, May 18 (HealthDay News) -- Although commonly used to treat heart disease, aspirin and simvastatin offer no benefit to patients suffering from pulmonary arterial hypertension, or PAH, a progressive disease characterized by increased blood pressure in the arteries of the lungs, according to new research.

In a study funded by the U.S. National Institutes of Health, researchers divided 65 patients into four groups: one receiving aspirin; one taking simvastatin; one receiving both drugs; and one in which patients received a placebo (or dummy pill).

"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population," said Dr. Steven Kawut, study lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine.

After taking the assigned medication for six months, patients were asked to see how far they could walk in six minutes. The distance tended to be shorter in the simvastatin group, and no difference was seen between the aspirin and placebo patients.

Following these early results, the U.S. National Heart, Lung, and Blood Institute discontinued the study based on a recommendation from the Data and Safety Monitoring Board.

"The results of this study do not support the routine treatment of PAH with these medications," Kawut said in an American Thoracic Society news release.

The findings are scheduled to be presented Wednesday at the American Thoracic Society international conference in Denver.

PAH, which is incurable, causes shortness of breath, dizziness and fatigue, and can lead to heart failure and death.

The researchers concluded that both aspirin and simvastatin may be prescribed for usual clinical indications in patients with PAH, but should not be administered specifically to treat PAH.

"The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled [randomized clinical trials] in humans before recommending their use," Kawut said.

Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on treatments for pulmonary arterial hypertension.

-- Mary Elizabeth Dallas

SOURCE: American Thoracic Society, news release, May 18, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. eHealthObjects chooses Elsevier/Gold Standard drug database
2. Human Factors/Ergonomics research leads to improved bunk bed safety standards
3. IOM recommends standards to achieve reliable clinical practice guidelines
4. Quality standards for widely used medicines strengthened
5. Federal Supply Schedule pricing added to ProspectoRx from Elsevier/Gold Standard
6. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
7. Community oncology: Ensuring the best standards of care
8. FDA Panel Recommends Tougher Standards for External Defibrillators
9. FDA Looking at Tougher Standards for External Defibrillators
10. FDA Looking for Tougher Standards for External Defibrillators
11. Universal standards proposed for prescription container labels to help reduce medication misuse
Post Your Comments:
Related Image:
Standard Heart Drugs Won't Ease Pulmonary Hypertension
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
Breaking Medicine Technology: